Organization
Lung & Gastrointestinal Oncology Department, Hunan Cancer Hospital, Changsha, China
2 abstracts
Abstract
Anti-TNFR2 monoclonal antibody LBL-019 in patients with advanced malignant tumors: A phase I, first-in-human, open-label, multicenter, dose escalation Study.Org: Department of Medical Oncology, Shanghai Pulmonary Hospital and Thoracic Cancer Institute, Tongji University School of Medicine, Shanghai, China, Department of Oncology, Fujian Cancer Hospital, Fuzhou, China, Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China, Lung & Gastrointestinal Oncology Department, Hunan Cancer Hospital, Changsha, China, Department of Internal Medicine-Oncology, Hubei Cancer Hospital, Wuhan, China,
Abstract
Efficacy and safety of IBI351 (GFH925) monotherapy in metastatic colorectal cancer harboring KRASG12C mutation: Preliminary results from a pooled analysis of two phase I studies.Org: Department of Medical Oncology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China, Department of Medical Oncology, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, China, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, China, The Sixth Affiliated Hospital, SYSU, Guangzhou, China, The Sixth Affiliated hospital, Sun Yat-sen University, Guangzhou, China, Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, China, Third Affiliated Hospital of Kunming Medical University, Kunming, China, Department of Colorectal Surgery, The Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou, China, Department of Medical Oncology, Sichuan Cancer Hospital, Chengdu, China, Department of Tumor Chemotherapy, Anhui Provincial Hospital, Hefei, China, Department of Oncology, The First Affiliated Hospital of Hunan Traditional Chinese Medical College, Zhuzhou, China,